The combined targeting of SOCS5 and the PI3K/Akt/mTOR pathway provides an attractive new option for impairing tumor metastasis, which is one of the main causes underlying the dismal prognosis of HCC patients. The gene discussed is MTOR; the disease is hepatocellular carcinoma.